{"title":"Two Cases of BRAF V600K Melanoma With Recurrence During Adjuvant Dabrafenib Plus Trametinib Therapy","authors":"Yuka Hatcho, Yukiko Kiniwa, Shiho Katsuie, Shoya Kitamura, Yuko Takazawa, Ryuhei Okuyama","doi":"10.1111/1346-8138.70018","DOIUrl":"10.1111/1346-8138.70018","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 1","pages":"e22-e23"},"PeriodicalIF":2.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Regaining Gait Independence in Idiopathic Inflammatory Myopathy Patients With Inability to Ambulate","authors":"Naoki Mugii, Yasuhito Hamaguchi, Goro Sakurai, Takashi Matsushita","doi":"10.1111/1346-8138.70020","DOIUrl":"10.1111/1346-8138.70020","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 11","pages":"1750-1752"},"PeriodicalIF":2.7,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145288064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shuji Suzuki, Keisuke Goto, Kazuyoshi Kajimoto, Koji Adachi, Takaya Fukumoto
We report two cases of folliculosebaceous poroma (holocrine poroma) harboring gene rearrangements involving members of the p21-activated kinase (PAK) family. Both tumors were composed of small poroid cells with ductal and sebaceous differentiation and demonstrated strong nuclear GATA3 expression on immunostaining. In one case, fluorescence in situ hybridization (FISH) demonstrated a PAK2 rearrangement; in the other, a PAK3 rearrangement was identified. Although GATA3 has been proposed as a useful marker to distinguish clonal seborrheic keratosis from hidroacanthoma simplex, its strong expression in PAK2/PAK3-rearranged folliculosebaceous poromas suggests limited specificity in this differential context. Notably, to our knowledge, this represents the first reported case of a benign poroma harboring a PAK3 rearrangement. These findings support a role for PAK gene fusions that may contribute to sebaceous differentiation in folliculosebaceous poroma and underscore the molecular heterogeneity of poromas.
{"title":"Folliculosebaceous Poromas With PAK2 and PAK3 Rearrangements: A Report of Two Cases and Review of the Literature","authors":"Shuji Suzuki, Keisuke Goto, Kazuyoshi Kajimoto, Koji Adachi, Takaya Fukumoto","doi":"10.1111/1346-8138.70014","DOIUrl":"10.1111/1346-8138.70014","url":null,"abstract":"<div>\u0000 \u0000 <p>We report two cases of folliculosebaceous poroma (holocrine poroma) harboring gene rearrangements involving members of the p21-activated kinase (<i>PAK</i>) family. Both tumors were composed of small poroid cells with ductal and sebaceous differentiation and demonstrated strong nuclear GATA3 expression on immunostaining. In one case, fluorescence in situ hybridization (FISH) demonstrated a <i>PAK2</i> rearrangement; in the other, a <i>PAK3</i> rearrangement was identified. Although GATA3 has been proposed as a useful marker to distinguish clonal seborrheic keratosis from hidroacanthoma simplex, its strong expression in <i>PAK2/PAK3</i>-rearranged folliculosebaceous poromas suggests limited specificity in this differential context. Notably, to our knowledge, this represents the first reported case of a benign poroma harboring a <i>PAK3</i> rearrangement. These findings support a role for <i>PAK</i> gene fusions that may contribute to sebaceous differentiation in folliculosebaceous poroma and underscore the molecular heterogeneity of poromas.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 12","pages":"1902-1905"},"PeriodicalIF":2.7,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145288107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"MVD-Nonsyndromic Epidermal Differentiation Disorder With a Previously Unreported Splice Variant in MVD Followed by Bullous Pemphigoid","authors":"Akira Miyazaki, Takuya Takeichi, Norito Ishii, Tomoo Ogi, Yoshinao Muro, Masashi Akiyama","doi":"10.1111/1346-8138.70016","DOIUrl":"10.1111/1346-8138.70016","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 1","pages":"e19-e21"},"PeriodicalIF":2.7,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Torii H, Morita A, Yamamoto C, Dong J, Tsujimoto M, Matsuo T, et al. Safety and Effectiveness of Ixekizumab in Japanese Patients With Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-Marketing Surveillance. The Journal of Dermatology, 52, no. 5 (2025): 787–801. https://doi.org/10.1111/1346-8138.17695.
We would like to clarify the Q2/Q2 dosing regimen for ixekizumab in the following parts of the above article.
The Abstract states:
Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from week 12) …
The Abstract text should be as follows:
Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks beyond week 12) …
The footnotes for Figure 1, Figure 4, Figure 5, state:
Q2/Q2, an initial ixekizumab dose of 160 mg, followed by 80 mg every 2 weeks from week 12; …
The footnotes should be as follows:
Q2/Q2, an initial ixekizumab dose of 160 mg, followed by 80 mg every 2 weeks beyond week 12; …
In section 3.1, there is an error in the following sentence:
Most patients had psoriasis vulgaris (n = 586 [72.9%]), followed by PsA (n = 30 [37.7%]), …
The correct sentence should be:
Most patients had psoriasis vulgaris (n = 586 [72.9%]), followed by PsA (n = 303 [37.7%]), …
There are errors in the values in Table 1. Under the column “Psoriasis vulgaris (N = 586)”, the value for the row “Comorbidities, n (%): Diabetes mellitus” is “7.9” and the value for the row “Biologic drug use, n (%)” is “46.3”. The values should be “7.8” and “46.2” respectively. Under the column “Pustular psoriasis (N = 63)”, the value for the row “Medical history, n (%)” is “19.1”. The value should be “19.0”.
The rows “Economic reasons” and “Not described” are missing from Table 2. The correct table is as follows:
There are errors in Table 3. The correct Table 3 is as follows:
There are errors in the values in Table 4. Under the column “Year 2 (N = 674)”, the values for the rows “Breast cancer recurrent”, “Prostate cancer”, “Lung adenocarcinoma stage I” and “Squamous cell carcinoma of skin” under “Benign, malignant, and unspecified neoplasms, n (%)” should be “1 (0.1)”.
{"title":"Correction to “Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance”","authors":"","doi":"10.1111/1346-8138.17976","DOIUrl":"10.1111/1346-8138.17976","url":null,"abstract":"<p>Torii H, Morita A, Yamamoto C, Dong J, Tsujimoto M, Matsuo T, et al. Safety and Effectiveness of Ixekizumab in Japanese Patients With Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-Marketing Surveillance. <i>The Journal of Dermatology</i>, 52, no. 5 (2025): 787–801. https://doi.org/10.1111/1346-8138.17695.</p><p>We would like to clarify the Q2/Q2 dosing regimen for ixekizumab in the following parts of the above article.</p><p>The Abstract states:</p><p>Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from week 12) …</p><p>The Abstract text should be as follows:</p><p>Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks beyond week 12) …</p><p>The footnotes for Figure 1, Figure 4, Figure 5, state:</p><p>Q2/Q2, an initial ixekizumab dose of 160 mg, followed by 80 mg every 2 weeks from week 12; …</p><p>The footnotes should be as follows:</p><p>Q2/Q2, an initial ixekizumab dose of 160 mg, followed by 80 mg every 2 weeks beyond week 12; …</p><p>In section 3.1, there is an error in the following sentence:</p><p>Most patients had psoriasis vulgaris (<i>n</i> = 586 [72.9%]), followed by PsA (<i>n</i> = 30 [37.7%]), …</p><p>The correct sentence should be:</p><p>Most patients had psoriasis vulgaris (<i>n</i> = 586 [72.9%]), followed by PsA (<i>n</i> = 303 [37.7%]), …</p><p>There are errors in the values in Table 1. Under the column “Psoriasis vulgaris (<i>N</i> = 586)”, the value for the row “Comorbidities, <i>n</i> (%): Diabetes mellitus” is “7.9” and the value for the row “Biologic drug use, <i>n</i> (%)” is “46.3”. The values should be “7.8” and “46.2” respectively. Under the column “Pustular psoriasis (<i>N</i> = 63)”, the value for the row “Medical history, <i>n</i> (%)” is “19.1”. The value should be “19.0”.</p><p>The rows “Economic reasons” and “Not described” are missing from Table 2. The correct table is as follows:</p><p>There are errors in Table 3. The correct Table 3 is as follows:</p><p>There are errors in the values in Table 4. Under the column “Year 2 (<i>N</i> = 674)”, the values for the rows “Breast cancer recurrent”, “Prostate cancer”, “Lung adenocarcinoma stage I” and “Squamous cell carcinoma of skin” under “Benign, malignant, and unspecified neoplasms, <i>n</i> (%)” should be “1 (0.1)”.</p><p>We sincerely apologize for these errors.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 11","pages":"1753-1757"},"PeriodicalIF":2.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145288104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Dermoscopic Findings in Merkel Cell Carcinoma in Japanese patients","authors":"Akinori Matsue, Junji Kato, Kohei Horimoto, Yoshiyuki Matsui, Tokimasa Hida, Hisashi Uhara","doi":"10.1111/1346-8138.70013","DOIUrl":"10.1111/1346-8138.70013","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 12","pages":"e1099-e1100"},"PeriodicalIF":2.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hyperpigmented Drug Eruption Caused by Sanshishi (Gardenia Fruit): A Rare and Potentially Overlooked Skin Manifestation","authors":"Wataru Hayashi, Misaki Kinoshita-Ise, Yoshiko Mizukawa, Manabu Ohyama","doi":"10.1111/1346-8138.70006","DOIUrl":"10.1111/1346-8138.70006","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 12","pages":"e1089-e1090"},"PeriodicalIF":2.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号